Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program ...

GSK enters oncology with Jemperli & Zejula for gynaecological cancers in India. Advanced therapies address unmet needs in ...

GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of ...

Karen Thursby, a Darlington -based yoga teacher who lost her mother Lola to bile duct cancer in 2017, has been organising ...

GlaxoSmithKline (GSK) has announced its foray into oncology in India with the launch of Jemperli (dostarlimab) and Zejula (niraparib). Jemperli is the first and only approved PD-1 immunotherapy for ...

GlaxoSmithKline (GSK) has entered India's oncology sector with the launch of Jemperli and Zejula. These therapies address the increasing need for specialized cancer treatments.